Subscribe to RSS
DOI: 10.1055/a-1957-5622
Adipositas aus viszeralonkologischer Perspektive
Obesity from the Perspective of Surgical Oncology
Zusammenfassung
Weltweit sind 40% der Erwachsenen von Übergewicht und Adipositas betroffen. Neben den bekannten adipositasassoziierten Komorbiditäten, wie Diabetes mellitus Typ 2, arteriellem Hypertonus oder der Steatosis hepatitis u. a., rückt der Einfluss eines erhöhten Körpergewichts auf das Risiko maligner Erkrankungen in den Fokus. Für mehr als 20 Tumorarten ist ein gewichtsabhängiger Prävalenzanstieg belegt, wobei die pathophysiologischen Einflüsse vielfältig sind und unterschiedlichste Aspekte der Tumorentstehung umfassen. Hier zu nennen sind chronische Entzündungsprozesse, Hyperinsulinämie und Insulinresistenz, verschiedene Wachstumsfaktoren und Geschlechtshormone. Auch im viszeralonkologischen Krankengut finden sich zahlreiche Tumoren, deren Erkrankungsrisiko mit dem Körpergewicht teilweise deutlich ansteigt. Dies zeigt sich u. a. beim kolorektalen Karzinom, hepatozellulären Karzinom, Adenokarzinom von Pankreas und Ösophagus sowie beim Kardiakarzinom. Da die Adipositas als grundsätzlich vermeidbare oder ursächlich behandelbare Krebsursache angesehen werden muss, beschäftigt sich diese Übersichtsarbeit zum einen mit dem Einfluss einer Adipositas auf die Prävalenz viszeralonkologisch relevanter Tumoren sowie deren Prävention und Therapie. Zum anderen wird die aktuelle Datenlage zum Einfluss adipositaschirurgischer Eingriffe auf die Tumorprävalenz dargestellt. Nach bariatrischen Eingriffen kann beim Adenokarzinom des Pankreas und beim hepatozellulären Karzinom eine deutlich geringere Malignomprävalenz beobachtet werden, gerade bei Letzterem kann dieser Effekt durch den mit der Gewichtsreduktion einhergehenden Rückgang der nicht alkoholischen Fettlebererkrankung (NAFLD) erklärt werden. Beim kolorektalen Karzinom hingegen zeigen die verfügbaren Daten ein eher inhomogenes Bild. Bei Malignomen des ösophagealen Übergangs wiederum wird, trotz der berechtigten Sorge, dass bariatrische Operationen (insbesondere die Schlauchmagenresektion) zu einer refluxbedingten erhöhten Prävalenz von Barrett-Karzinomen führen, keine relevante Erhöhung der Malignomrate beobachtet.
Abstract
Up to 40% of all adults worldwide are overweight or obese. Besides the established obesity-related comorbidities, such as type 2 diabetes mellitus, hypertension or NAFLD (non-alcoholic fatty liver disease), the focus of interest is shifting towards the influence of increased body weight as a risk factor for the development of malignant diseases. For more than 20 different types of malignancies, interactions between increased body weight and cancer risk have been established. Pathophysiological influences of obesity on carcinogenesis are diverse, including factors such as chronic inflammation, hyperinsulinaemia and insulin resistance, various changes in growth factor and changes in sex hormones. In cohorts of visceral oncology patients, malignancies such as colorectal carcinomas, hepatocellular carcinomas, adenocarcinomas of the pancreas, oesophageal and gastric carcinomas are also linked to an increased disease risk with increasing body weight. Since obesity must be considered a preventable or at least treatable cause of cancer, this review examines the influence of obesity in the field of visceral oncology, examining the effects of obesity on tumour prevalence, prevention and diagnostic testing, as well as its influence on treatment and prognosis. Furthermore, this review explores the current evidence on the influence of bariatric surgery on the prevalence of these obesity associated tumours. For example, in the case of colorectal carcinomas, the evidence base following bariatric surgery is mixed, painting an inhomogeneous picture. On the other hand, significantly lower prevalence of pancreatic adenocarcinoma and hepatocellular carcinomas is to be noted. The latter effect can be explained by the decrease in non-alcoholic fatty liver disease (NAFLD) associated with weight loss. Despite the justified concern that bariatric procedures (especially gastric sleeve resection) lead to increased prevalence of malignancies of the oesophageal junction, the currently available epidemiological data does not seem to identify a relevant increase in the incidence of these malignancies.
Publication History
Received: 13 June 2022
Accepted after revision: 16 September 2022
Article published online:
07 December 2022
© 2022. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Bluher M. [Conservative obesity treatment – when and how?]. Dtsch Med Wochenschr 2015; 140: 24-28
- 2 NCDRisk Factors Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet 2016; 387: 1377-1396
- 3 Dietrich A, Aberle J, Wirth A. et al. Obesity Surgery and the Treatment of Metabolic Diseases. Dtsch Arztebl Int 2018; 115: 705-711
- 4 Katz A. CE: Obesity-Related Cancer in Women: A Clinical Review. Am J Nurs 2019; 119: 34-40
- 5 Wynder EL, Escher GC, Mantel N. An epidemiological investigation of cancer of the endometrium. Cancer 1966; 19: 489-520
- 6 Steele CB, Thomas CC, Henley SJ. et al. Vital Signs: Trends in Incidence of Cancers Associated with Overweight and Obesity – United States, 2005–2014. MMWR Morb Mortal Wkly Rep 2017; 66: 1052-1058
- 7 Lauby-Secretan B, Scoccianti C, Loomis D. et al. Body Fatness and Cancer--Viewpoint of the IARC Working Group. N Engl J Med 2016; 375: 794-798
- 8 Bhaskaran K, Douglas I, Forbes H. et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet 2014; 384: 755-765
- 9 Haug U. [Current evidence and development of colorectal cancer screening in Germany]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2018; 61: 1513-1516
- 10 Gutin I. Body mass index is just a number: Conflating riskiness and unhealthiness in discourse on body size. Sociol Health Illn 2021; 43: 1437-1453
- 11 Houghton SC, Eliassen H, Tamimi RM. et al. Central Adiposity and Subsequent Risk of Breast Cancer by Menopause Status. J Natl Cancer Inst 2021; 113: 900-908
- 12 Behrens G, Gredner T, Stock C. et al. Cancers Due to Excess Weight, Low Physical Activity, and Unhealthy Diet. Dtsch Arztebl Int 2018; 115: 578-585
- 13 Shrotriya S, Walsh D, Nowacki AS. et al. Serum C-reactive protein is an important and powerful prognostic biomarker in most adult solid tumors. PLoS One 2018; 13: e0202555
- 14 Tsujimoto T, Kajio H, Sugiyama T. Association between hyperinsulinemia and increased risk of cancer death in nonobese and obese people: A population-based observational study. Int J Cancer 2017; 141: 102-111
- 15 Kolbl H, Bartl T. Obesity in Gynecologic Oncology. Geburtshilfe Frauenheilkd 2020; 80: 1205-1211
- 16 Célind J, Bygdell M, Martikainen J. et al. Childhood overweight and risk of obesity-related adult cancer in men. Cancer Commun (Lond) 2022; 42: 576-579
- 17 Kheniser K, Saxon DR, Kashyap SR. Long-Term Weight Loss Strategies for Obesity. J Clin Endocrinol Metab 2021; 106: 1854-1866
- 18 Wadden TA. Treatment of obesity by moderate and severe caloric restriction. Results of clinical research trials. Ann Intern Med 1993; 119: 688-693
- 19 Kirwan JP, Courcoulas AP, Cummings DE. et al. Diabetes Remission in the Alliance of Randomized Trials of Medicine Versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D). Diabetes Care 2022; 45: 1574-1583
- 20 Sjöholm K, Carlsson LMS, Svensson PA. et al. Association of Bariatric Surgery With Cancer Incidence in Patients With Obesity and Diabetes: Long-term Results From the Swedish Obese Subjects Study. Diabetes Care 2022; 45: 444-450
- 21 Schauer DP, Feigelson HS, Koebnick C. et al. Bariatric Surgery and the Risk of Cancer in a Large Multisite Cohort. Ann Surg 2019; 269: 95-101
- 22 Zhang K, Luo Y, Dai H. et al. Effects of Bariatric Surgery on Cancer Risk: Evidence from Meta-analysis. Obes Surg 2020; 30: 1265-1272
- 23 Aminian A, Wilson R, Al-Kurd A. et al. Association of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity. JAMA 2022; 327: 2423-2433
- 24 Cooper AJ, Gupta SR, Moustafa AF. et al. Sex/Gender Differences in Obesity Prevalence, Comorbidities, and Treatment. Curr Obes Rep 2021; 10: 458-466
- 25 Hölzel D, Schubert-Fritschle G, Schmidt M. et al. [Clinical and epidemiological cancer registration in Germany]. Pathologe 2016; 37: 371-387
- 26 Duggan C, Tapsoba JD, Stanczyk F. et al. Long-term weight loss maintenance, sex steroid hormones, and sex hormone-binding globulin. Menopause 2019; 26: 417-422
- 27 Sung H, Ferlay J, Siegel RL. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71: 209-249
- 28 World Cancer Research Fund, American Institute for Cancer Research. Continuous Update Project Expert Report 2018. Body fatness and weight gain and the risk of cancer. Accessed October 18, 2022 at: https://www.wcrf.org/wp-content/uploads/2021/01/Body-fatness-and-weight-gain_0.pdf
- 29 Nielsen JB, Berg-Beckhoff G, Leppin A. To do or not to do – a survey study on factors associated with participating in the Danish screening program for colorectal cancer. BMC Health Serv Res 2021; 21: 43
- 30 Passi M, Rahman F, Koh C. et al. Efficacy and tolerability of colonoscopies in overweight and obese patients: Results from a national database on gastrointestinal endoscopic outcomes. Endosc Int Open 2022; 10: E311-E320
- 31 Huo D, Rill L. Hallway Conversations in PhysicsWhat Is the Relative Radiation Dose Increase for an Obese Patient Undergoing Radiography, Fluoroscopy, and CT Examinations?. AJR Am J Roentgenol 2017; 208: W56-W57
- 32 Uppot RN. Technical challenges of imaging & image-guided interventions in obese patients. Br J Radiol 2018; 91: 20170931
- 33 Nugent TS, Kelly ME, Donlon NE. et al. Obesity and anastomotic leak rates in colorectal cancer: a meta-analysis. Int J Colorectal Dis 2021; 36: 1819-1829
- 34 Qiu Y, Liu Q, Chen G. et al. Outcome of rectal cancer surgery in obese and nonobese patients: a meta-analysis. World J Surg Oncol 2016; 14: 23
- 35 Fung A, Trabulsi N, Morris M. et al. Laparoscopic colorectal cancer resections in the obese: a systematic review. Surg Endosc 2017; 31: 2072-2088
- 36 Abd El Aziz MA, Grass F, Perry W. et al. Colectomy for patients with super obesity: current practice and surgical morbidity in the United States. Surg Obes Relat Dis 2020; 16: 1764-1769
- 37 Lee SY, Kim CH, Kim YJ. et al. Obesity as an independent predictive factor for pathologic complete response after neoadjuvant chemoradiation in rectal cancer. Ann Surg Treat Res 2019; 96: 116-122
- 38 Sun Y, Xu Z, Lin H. et al. Impact of body mass index on treatment outcome of neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Eur J Surg Oncol 2017; 43: 1828-1834
- 39 Diefenhardt M, Ludmir EB, Hofheinz RD. et al. Impact of body-mass index on treatment and outcome in locally advanced rectal cancer: A secondary, post-hoc analysis of the CAO/ARO/AIO-04 randomized phase III trial. Radiother Oncol 2021; 164: 223-231
- 40 Bailly L, Fabre R, Pradier C. et al. Colorectal Cancer Risk Following Bariatric Surgery in a Nationwide Study of French Individuals With Obesity. JAMA Surg 2020; 155: 395-402
- 41 Almazeedi S, El-Abd R, Al-Khamis A. et al. Role of bariatric surgery in reducing the risk of colorectal cancer: a meta-analysis. Br J Surg 2020; 107: 348-354
- 42 Tao W, Artama M, von Euler-Chelpin M. et al. Colon and rectal cancer risk after bariatric surgery in a multicountry Nordic cohort study. Int J Cancer 2020; 147: 728-735
- 43 Mackenzie H, Markar SR, Askari A. et al. Obesity surgery and risk of cancer. Br J Surg 2018; 105: 1650-1657
- 44 Taube M, Peltonen M, Sjöholm K. et al. Long-term incidence of colorectal cancer after bariatric surgery or usual care in the Swedish Obese Subjects study. PLoS One 2021; 16: e0248550
- 45 Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet 2021; 397: 2212-2224
- 46 Younossi ZM, Koenig AB, Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84
- 47 Estes C, Anstee QM, Arias-Loste MT. et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol 2018; 69: 896-904
- 48 Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism 2019; 92: 82-97
- 49 Bechmann LP, Hannivoort RA, Gerken G. et al. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol 2012; 56: 952-964
- 50 Bataller R, Rombouts K, Altamirano J. et al. Fibrosis in alcoholic and nonalcoholic steatohepatitis. Best Pract Res Clin Gastroenterol 2011; 25: 231-244
- 51 Ertle J, Dechene A, Sowa JP. et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011; 128: 2436-2443
- 52 Loomba R, Yang HI, Su J. et al. Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. Am J Epidemiol 2013; 177: 333-342
- 53 Esfeh JM, Hajifathalian K, Ansari-Gilani K. Sensitivity of ultrasound in detecting hepatocellular carcinoma in obese patients compared to explant pathology as the gold standard. Clin Mol Hepatol 2020; 26: 54-59
- 54 Acosta LF, Garcia CR, Dugan A. et al. Impact of super obesity on perioperative outcomes after hepatectomy: The weight of the risk. Surgery 2017; 162: 1026-1031
- 55 Kwak M, Mehaffey JH, Hawkins RB. et al. Bariatric surgery is associated with reduction in non-alcoholic steatohepatitis and hepatocellular carcinoma: A propensity matched analysis. Am J Surg 2020; 219: 504-507
- 56 Ramai D, Singh J, Lester J. et al. Systematic review with meta-analysis: bariatric surgery reduces the incidence of hepatocellular carcinoma. Aliment Pharmacol Ther 2021; 53: 977-984
- 57 Manabe N, Matsueda K, Haruma K. Epidemiological Review of Gastroesophageal Junction Adenocarcinoma in Asian Countries. Digestion 2022; 103: 29-36
- 58 Sharma N, Ho KY. Risk Factors for Barrett’s Oesophagus. Gastrointest Tumors 2016; 3: 103-108
- 59 Kilic ET, Sayar S, Kahraman R. et al. The effects of obesity on sedation-related outcomes of advanced endoscopic procedures. North Clin Istanb 2019; 6: 321-326
- 60 Wang J, Myles B, Wei C. et al. Obesity and outcomes in patients treated with chemoradiotherapy for esophageal carcinoma. Dis Esophagus 2014; 27: 168-175
- 61 Mengardo V, Pucetti F, Mc Cormack O. et al. The impact of obesity on esophagectomy: a meta-analysis. Dis Esophagus 2018; 31
- 62 Ri M, Aikou S, Seto Y. Obesity as a surgical risk factor. Ann Gastroenterol Surg 2018; 2: 13-21
- 63 Lee DH, Giovannucci EL. The Obesity Paradox in Cancer: Epidemiologic Insights and Perspectives. Curr Nutr Rep 2019; 8: 175-181
- 64 Maret-Ouda J, Tao W, Mattsson F. et al. Esophageal adenocarcinoma after obesity surgery in a population-based cohort study. Surg Obes Relat Dis 2017; 13: 28-34
- 65 Papadia FS, Marabotto E, Mascherini M. et al. Sleeve gastrectomy may double the risk of esophageal adenocarcinoma in morbidly obese patients. Surg Obes Relat Dis 2021; 17: 1029-1030
- 66 Genco A, Castagneto-Gissey L, Casella G. Response to: Sleeve gastrectomy may double the risk of esophageal adenocarcinoma in morbidly obese patients. Surg Obes Relat Dis 2021; 17: 1030
- 67 Qumseya BJ, Qumsiyeh Y, Ponniah SA. et al. Barrett’s esophagus after sleeve gastrectomy: a systematic review and meta-analysis. Gastrointest Endosc 2021; 93: 343-352.e2
- 68 Andalib A, Bouchard P, Demyttenaere S. et al. Esophageal cancer after sleeve gastrectomy: a population-based comparative cohort study. Surg Obes Relat Dis 2021; 17: 879-887
- 69 Lattimore CM, Kane WJ, Turrentine FE. et al. The impact of obesity and severe obesity on postoperative outcomes after pancreatoduodenectomy. Surgery 2021; 170: 1538-1545
- 70 Zorbas K, Wu J, Reddy S. et al. Obesity affects outcomes of pancreatoduodenectomy. Pancreatology 2021; 21: 824-832
- 71 Rustgi VK, Li Y, Gupta K. et al. Bariatric Surgery Reduces Cancer Risk in Adults With Nonalcoholic Fatty Liver Disease and Severe Obesity. Gastroenterology 2021; 161: 171-184 e110
- 72 Christou NV, Lieberman M, Sampalis F. et al. Bariatric surgery reduces cancer risk in morbidly obese patients. Surg Obes Relat Dis 2008; 4: 691-695
- 73 Adams TD, Stroup AM, Gress RE. et al. Cancer incidence and mortality after gastric bypass surgery. Obesity (Silver Spring) 2009; 17: 796-802